Impact of gabapentinoids' reclassification policy and COVID-19 on gabapentinoids' utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis.

BACKGROUND: Gabapentinoids are commonly used for neuropathic pain but are increasingly linked with misuse/mortality. In 2019, the UK reclassified them as Schedule 3 controlled drugs. The onset of the COVID-19 pandemic created additional uncertainty r…

Preview only. Read the full abstract at the source